Haemolytic Anaemia

The answer first

Haemolytic Anaemia is managed with an answer-first physician approach: recognise the pattern, exclude dangerous differentials, choose investigations that change action, and deliver a sequenced management plan that accounts for multimorbidity. [1] [2]

The FRACP candidate must be able to open a long-case presentation, defend thresholds, and answer DWE vignettes without hedging. Lead with the decision, then the evidence and the trap. [1]

Clinical spectrum and red flags

Presentations range from incidental or outpatient findings to emergency decompensation. Always ask what would make this urgent today — airway, perfusion, neurological threat, metabolic crisis, infection, or bleeding. [1] [2]

Red flags force same-day action rather than elective pathways. Document them explicitly in the plan. [1]

Classification that changes management

Classify by acuity, mechanism, severity and care setting. A useful classification changes investigation choice, initial therapy, disposition or specialist referral — otherwise it is taxonomy without purpose. [1] [2]

Pathophysiology linked to bedside decisions

Mechanism matters when it predicts treatment response, complications or monitoring. Teach pathophysiology as a bridge to action, not as isolated basic science. [1] [2] [3]

Differentials and discrimination

Build a short differential that includes the common, the dangerous and the commonly missed. For each alternative, name one history clue, one examination clue and one investigation that discriminates. [1] [2]

Investigations

Order tests that change management. State what is required now, what can wait, and what is low-value or harmful. Interpret results in clinical context rather than in isolation. [1] [2]

Management — immediate then definitive

1. Stabilise threats to life and organ function. [1]
2. Start disease-specific therapy once the working diagnosis is secure enough to act. [1] [2]
3. Address complications, drug interactions and monitoring. [1] [2]
4. Plan disposition, follow-up intensity and patient education with safety-net advice. [1]

Complications and prognosis

Anticipate early and late complications. Prognosis depends on severity at presentation, speed of effective therapy, comorbidity and adherence to secondary prevention or disease-modifying treatment. [1] [2]

Special populations and multimorbidity

Adjust for pregnancy potential, frailty, CKD, liver disease, immunosuppression and polypharmacy. In older adults, goals-of-care and treatment burden can change the preferred plan even when disease-directed options remain available. [1] [2]

DCE long-case angles

Open with a one-sentence synthesis, then a prioritised problem list, then an integrated plan covering investigations, treatment, prevention and communication. Link Haemolytic Anaemia to cardiovascular risk, infection risk, medications and social context where relevant. [1] [2]

DCE short-case angles

Be prepared to demonstrate or discuss focused examination findings, interpret a key investigation, and counsel on risks, benefits and follow-up in plain language. [1]

Exam traps

1. Delaying urgent care because the presentation looks "stable enough". [1]
2. Treating a syndrome label without confirming mechanism. [1] [2]
3. Forgetting drug interactions and organ-function dosing. [1] [2]
4. Omitting safety-net advice and follow-up ownership. [1]
5. Quoting thresholds without knowing the source trial or guideline. [1] [2] [3]

References

1. [1]Dhaese S, Van den Bergh B, De Vriese A Off the Beaten Path: Pathogenic Mechanisms and Therapeutic Implications in Non-Complement Mediated Thrombotic Microangiopathies Kidney360, 2026.PMID 42467940
2. [2]Duca L, Fermo E, Bianchi P, Vercellati C, et al. Integrated enzymatic and molecular diagnosis of G6PD deficiency: a one-year experience identifying five novel variants Ann Hematol, 2026.PMID 42467236
3. [3]Peña Monge EM, Carrasco-Randrianarison N, Ponte-Fernandez K Secondary Evans Syndrome Associated with Localized Clear Cell Renal Cell Carcinoma: A Case Report and Brief Literature Review Eur J Case Rep Intern Med, 2026.PMID 42466227
4. [4]Dehghani M, Sariri F, Zeinalian M Recurrent perianal abscess and fistula in a patient with Glucose-6-phosphate dehydrogenase (G6PD) deficiency: a case report BMC Gastroenterol, 2026.PMID 42316031
5. [5]Chen X, Huang J, Shen Z, Zhu Q, et al. Erythrodermic psoriasis complicated by immune complex-mediated crescentic glomerulonephritis and atypical hemolytic uremic syndrome: a case report BMC Nephrol, 2026.PMID 41866478
6. [6]Doan HN, Chang MC Comparative Effectiveness of Unstable Versus Stable Resistance Training on Lower Limb Strength, Mobility, and Fear of Falling in Older Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials Am J Phys Med Rehabil, 2026.PMID 42468010
7. [7]Liu HW, Tsai TL Virtual Reality-assisted Physiotherapeutic Training for Patients With Knee Osteoarthritis: A Systematic Review and Meta-analysis Am J Phys Med Rehabil, 2026.PMID 42468005
8. [8]Osborne AK, Brown RD, Sillence E Effects of Social Media Narratives on Affective and Behavioral Responses to Menopause Content: Randomized Online Experimental Study JMIR Form Res, 2026.PMID 42467962
9. [9]Belkhribchia MR, Vallat JM, Lahoucine T, Danigo A, et al. Fulminant Evans Syndrome and Splenic Infarction As Initial Manifestations of Poems Syndrome with Monoclonal Kappa Light Chain Restriction: A Diagnostic and Therapeutic Challenge Eur J Case Rep Intern Med, 2026.PMID 42466217
10. [10]Rodrigues IV, Pimenta de Castro A, Rios E, Barbosa I, et al. Severe Immune-Mediated Thrombotic Thrombocytopenic Purpura With High-Titer ADAMTS13 Inhibitors: A Case Report Cureus, 2026.PMID 42445863
11. [11]Piva E, Pelloso M, Tosato F, Padoan A, et al. Performance of the CellaVision advanced RBC application for schistocyte counting in the emergency clinical laboratory Clin Chem Lab Med, 2026.PMID 42443137
12. [12]Dai Y, Su S, Zhou K, Lu X Identification of a novel hereditary spherocytosis gene mutation in a Chinese child with α-globin gene triplication MedScience, 2026.PMID 42467362